cyclohexadecylamine | 116601-55-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: cyclohexadecylamine
• 英文别名: Cyclohexadecylamin；cyclohexadecanamine
• CAS: 116601-55-9
• 化学式: C₁₆H₃₃N
• 分子量: 239.445
• InChiKey: XFCCDKMYFFDSBJ-UHFFFAOYSA-N

物化性质

• 沸点：
  108-110 °C(Press: 0.06-7 Torr)
• 密度：
  0.821±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  聚合甲醛 、 cyclohexadecylamine 生成 Cyclohexadecyl-dimethyl-amin
  参考文献：
  名称：

  Zavada,J. et al., Collection of Czechoslovak Chemical Communications, 1966, vol. 31, p. 4273 - 4285

  摘要：

  DOI：
• 作为产物：
  描述：

  cyclohexadecanone oxime 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 cyclohexadecylamine
  参考文献：
  名称：

  Reactivity of electron impact ionized large-ring cycloalkylamines. Loss ofCnH2n + 1. Alkyl radicals from long-chain aliphatic compounds with a terminal enamine or ester function (lipids)

  摘要：

  AbstractLarge‐ring Cycloalkylamines rearrange after electron impact ionization into long‐chain enamines. A general mechanism is proposed for their fragmentation, and a parallel is established with the fragmentation of long‐chain esters (lipids). It is shown that the parent ions rearrange into a series of interconverting branched onium ions from which alkyl radicals are lost. The mechanism of the interconversion is discussed.

  DOI：

  10.1002/oms.1210270509

文献信息

• [EN] N-(MONOCYCLIC ARYL),N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS<br/>[FR] COMPOSÉS DE N-ARYLE MONOCYCLIQUES, N'-PYRAZOLYL-URÉE, THIOURÉE, GUANIDINE ET CYANOGUANIDINE UTILES COMME INHIBITEURS DE TRKA KINASE
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2014078325A1

  公开（公告）日：2014-05-22

  Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

  化合物的公式(I)或其立体异构体、互变异构体、或其药学上可接受的盐、溶剂合物或前药，其中环A、环C和X如本文所定义，是TrkA激酶的抑制剂，并且在治疗可以用TrkA激酶抑制剂治疗的疾病中具有用处，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、干燥综合征、子宫内膜异位症、糖尿病周围神经病变、前列腺炎或盆腔疼痛综合征。
• Heteroatom bridged metallocene compounds for olefin polymerization
  申请人：Voskoboynikov Z. Alexander

  公开号：US20070135597A1

  公开（公告）日：2007-06-14

  This invention relates to a transition metal compound represented by the formula: wherein M is a group 3, 4, 5 or 6 transition metal atom, or a lanthanide metal atom, or actinide metal atom; E is: 1) a substituted or unsubstituted indenyl ligand that is bonded to Y through the four, five, six or seven position of the indenyl ring, or 2) a substituted or unsubstituted heteroindenyl ligand that is bonded to Y through the four, five or six position of the heteroindenyl ring, provided that the bonding position is not the same as the position of the ring heteroatom, or 3) a substituted or unsubstituted fluorenyl ligand that is bonded to Y through the one, two, three, four, five, six, seven or eight position of the fluorenyl ring, or 4) a substituted or unsubstituted heterofluorenyl ligand that is bonded to Y through the one, two, three, four, five or six position of the heteroindenyl ring, provided that the bonding position is not the same as the position of the ring heteroatom; A is a substituted or unsubstituted cyclopentadienyl ligand, a substituted or unsubstituted heterocyclopentadienyl ligand, a substituted or unsubstituted indenyl ligand, a substituted or unsubstituted heteroindenyl ligand, a substituted or unsubstituted fluorenyl ligand, a substituted or unsubstituted heterofluorenyl ligand, or other mono-anionic ligand; Y is a Group 15 or 16 bridging heteroatom substituent that is bonded via the heteroatom to E and A; and X are, independently, univalent anionic ligands, or both X are joined and bound to the metal atom to form a metallocycle ring, or both X join to form a chelating ligand, a diene ligand, or an alkylidene ligand. This invention further relates to catalyst systems comprising the above transiotioon metal compounds, activators and optional supports and their use to polymerize or oligomerize olefins.

  本发明涉及一种过渡金属化合物，其表示为以下公式：其中M是3、4、5或6族过渡金属原子，或镧系金属原子，或锕系金属原子；E是：1）与Y通过茚环的四、五、六或七位置结合的取代或未取代的茚基配体，或2）与Y通过杂环茚环的四、五或六位置结合的取代或未取代的杂环茚基配体，前提是结合位置与环杂原子的位置不同，或3）与Y通过芴环的一、二、三、四、五、六、七或八位置结合的取代或未取代的芴基配体，或4）与Y通过杂芴环的一、二、三、四、五或六位置结合的取代或未取代的杂芴基配体，前提是结合位置与环杂原子的位置不同；A是取代或未取代的环戊二烯基配体，取代或未取代的杂环戊二烯基配体，取代或未取代的茚基配体，取代或未取代的杂环茚基配体，取代或未取代的芴基配体，取代或未取代的杂芴基配体，或其他单阴离子配体；Y是通过杂原子与E和A结合的15族或16族桥接杂原子取代基；X是独立的一价阴离子配体，或两个X结合并与金属原子结合形成金属环，或两个X结合形成螯合配体、二烯基配体或烷基亚基配体。本发明还涉及包含上述过渡金属化合物、活化剂和可选支撑物的催化剂系统及其用于聚合或寡聚烯烃的用途。
• Verwendung von Perylenfarbstoffen zur Herstellung von Schreib-, Druck- und Kopiererzeugnissen
  申请人：RIEDEL-DE HAEN AKTIENGESELLSCHAFT

  公开号：EP0446748A2

  公开（公告）日：1991-09-18

  Die vorliegende Erfindung betrifft die Verwendung von Farbstoffen der allgemeinen Formel I worin R¹ und R² wie in der Beschreibung angegeben definiert sind zur Herstellung von dokumentenechten Schreib-, Druck- und Kopier-Erzeugnissen.

  本发明涉及通式 I 着色剂的使用 其中 R¹ 和 R² 的定义如描述中所示，用于生产快速书写、打印和复印产品。
• Perylenhydrazidimide als Carbonylderivatisierungsreagenzien
  申请人：Ciba Specialty Chemicals Holding Inc.

  公开号：EP0896964A2

  公开（公告）日：1999-02-17

  Perylenhydrazid-imide der allgemeinen Formel I ein Verfahren zu dessen Herstellung, die Verwendung als Nachweisreagenz für Carbonylverbindungen, Protonensäuren, Acylierungsmitteln und Metallsalzen sowie Perylenhydrazone II und bi- und trifluorophore Perylenbisimide III, deren Herstellung und Verwendung.

  一种式 I 的过烯酰肼亚胺 的制备方法，其作为羰基化合物、质子酸、酰化剂和金属盐的检测试剂的用途，以及过烯酰肼 II 和双氟和三氟过烯双酰亚胺 III 的制备和用途。
• METHOD OF SYNTHESIS AND TESTING OF COMBINATORIAL LIBRARIES USING MICROCAPSULES
  申请人：United Kingdom Research and Innovation

  公开号：EP3524344A1

  公开（公告）日：2019-08-14

  The invention describes a method for the synthesis of compounds comprising the steps of: (a) compartmentalising two or more sets of primary compounds into microcapsules; such that a proportion of the microcapsules contains two or more compounds; and (b) forming secondary compounds in the microcapsules by chemical reactions between primary compounds from different sets. The invention further allows for the identification of compounds which bind to a target component of a biochemical system or modulate the activity of the target, and which is co-compartmentalised into the microcapsules.

  本发明描述了一种合成化合物的方法，包括以下步骤(a) 将两组或两组以上的主要化合物分隔成微胶囊；使一定比例的微胶囊含有两种或两种以上的化合物；以及 (b) 通过来自不同组的主要化合物之间的化学反应，在微胶囊中形成次要化合物。本发明还可进一步鉴定与生化系统的目标成分结合或调节目标活性的化合物，并将其共同分装到微胶囊中。